Published by Coherent Market Insights
Posted on September 17, 2021
Renal bypass surgery is a minimally invasive surgical method to treat chronic hypertension. Patients who have congestive heart failure are candidates for this procedure, which improves blood flow in the body by bypassing the organ. A balloon catheter is inflated to increase blood flow in the body’s extremities such as legs and feet. This balloon catheter is attached to a thin tube that empties it into the abdominal cavity. As far as the regional footprint is considered, Europe seems to be gaining robust traction in the renal denervation devices market. This is typically due to the fact there is an increasing prevalence of cardiovascular diseases in the region. On the contrary, Europe seems to exhibit promising signs with rising occurrence of diabetes in emerging economies.
The PDF for the study can be requested using the following link: https://www.coherentmarketinsights.com/insight/request-pdf/798
The typical application of renal denervation devices is in the treatment of resistant hypertension. Over the years, hypertension has become one of the most significant lifestyle diseases, which could lead to various other health-related complications. As per the Centers for Disease Control and Prevention (CDC), in the U.S., in 2020, around 108 million people have hypertension, which is defined as systolic blood pressure. Furthermore, according to the American Institute of Stress, in 2020, around 33% of people report extreme stress in the U.S. Such a high incidence of hypertension and stress is necessitating adequate treatment options. Hence, such factors can stimulate growth of the renal denervation devices market.
The global renal denervation devices market size was valued at US$ 88.6 million in 2020, and is expected to exhibit a CAGR of 35.5% over the forecast period (2021 – 2027).
That being said, there are certain factors that can pose a major challenge to the growth of the market. For instance, renal denervation procedure is highly painful, and thus many patients tend to opt for minimally invasive surgical procedures. Besides, stringent regulations on product approvals and reimbursement systems can potentially impede growth of the renal denervation devices market in the near future.
One of the major advantages of renal denervation devices is that these devices offer long-lasting effects as compared to other surgical procedures. Besides, over the years, these devices have improved significantly due to technological advancements and continuous research and development activities by key medical device manufacturers. Therefore, these factors can potentially augment growth of the renal denervation devices market in the near future. Recently, in March 2020, Medtronic plc announced the first-ever clinical data from the SPYRAL HTN-OFF MED Pivotal Trial, which showed superiority for renal denervation in patients with high blood pressure as compared to the Sham procedure.
Top Key Players Include In Renal Denervation Devices Market: St. Jude Medical, Inc., ReCor Medical Inc., Boston Scientific Corporation, Cardiosonic Ltd, Medtronic Plc., Kona Medical, Inc., Mercator Medsystems, Inc., Terumo Corporation, Abbott Laboratories, and Theragenics Corporation.
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/798
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
The post Renal Denervation Devices Market Global Status and Business Outlook 2021 to 2027 appeared first on Gatorledger.
Renal bypass surgery is a minimally invasive surgical method to treat chronic hypertension. Patients who have congestive heart failure are candidates for this procedure, which improves blood flow in the body by bypassing the organ. A balloon catheter is inflated to increase blood flow in the body’s extremities such as legs and feet. This balloon catheter is attached to a thin tube that empties it into the abdominal cavity. As far as the regional footprint is considered, Europe seems to be gaining robust traction in the renal denervation devices market. This is typically due to the fact there is an increasing prevalence of cardiovascular diseases in the region. On the contrary, Europe seems to exhibit promising signs with rising occurrence of diabetes in emerging economies.
The PDF for the study can be requested using the following link: https://www.coherentmarketinsights.com/insight/request-pdf/798
The typical application of renal denervation devices is in the treatment of resistant hypertension. Over the years, hypertension has become one of the most significant lifestyle diseases, which could lead to various other health-related complications. As per the Centers for Disease Control and Prevention (CDC), in the U.S., in 2020, around 108 million people have hypertension, which is defined as systolic blood pressure. Furthermore, according to the American Institute of Stress, in 2020, around 33% of people report extreme stress in the U.S. Such a high incidence of hypertension and stress is necessitating adequate treatment options. Hence, such factors can stimulate growth of the renal denervation devices market.
The global renal denervation devices market size was valued at US$ 88.6 million in 2020, and is expected to exhibit a CAGR of 35.5% over the forecast period (2021 – 2027).
That being said, there are certain factors that can pose a major challenge to the growth of the market. For instance, renal denervation procedure is highly painful, and thus many patients tend to opt for minimally invasive surgical procedures. Besides, stringent regulations on product approvals and reimbursement systems can potentially impede growth of the renal denervation devices market in the near future.
One of the major advantages of renal denervation devices is that these devices offer long-lasting effects as compared to other surgical procedures. Besides, over the years, these devices have improved significantly due to technological advancements and continuous research and development activities by key medical device manufacturers. Therefore, these factors can potentially augment growth of the renal denervation devices market in the near future. Recently, in March 2020, Medtronic plc announced the first-ever clinical data from the SPYRAL HTN-OFF MED Pivotal Trial, which showed superiority for renal denervation in patients with high blood pressure as compared to the Sham procedure.
Top Key Players Include In Renal Denervation Devices Market: St. Jude Medical, Inc., ReCor Medical Inc., Boston Scientific Corporation, Cardiosonic Ltd, Medtronic Plc., Kona Medical, Inc., Mercator Medsystems, Inc., Terumo Corporation, Abbott Laboratories, and Theragenics Corporation.
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/798
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
The post Renal Denervation Devices Market Global Status and Business Outlook 2021 to 2027 appeared first on Gatorledger.
Explore more articles in the Research Reports category
